Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Asymptomatic SARS-CoV-2 Detection in Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04853316
Recruitment Status : Active, not recruiting
First Posted : April 21, 2021
Last Update Posted : May 18, 2022
Sponsor:
Collaborator:
Canadian Institutes of Health Research (CIHR)
Information provided by (Responsible Party):
University of Calgary

Brief Summary:
The primary objective of this study is quantify the transmission risk posted by SARS-CoV-2 in pre/asymptomatic infected children in order to inform the public health response to the COVID-19 pandemic.

Condition or disease
Covid19 SARS-CoV-2

Show Show detailed description

Layout table for study information
Study Type : Observational
Actual Enrollment : 372 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Household Transmission Dynamics and Viral Load Among Asymptomatic SARS-CoV-2 Infected Children
Actual Study Start Date : November 16, 2020
Estimated Primary Completion Date : June 30, 2022
Estimated Study Completion Date : June 30, 2022

Resource links provided by the National Library of Medicine


Group/Cohort
Case: Exposed (SARS-CoV-2 positive)
Participants found positive by SARS-CoV-2 testing.
Control: Unexposed (SARS-CoV-2 negative)
Participants found negative by SARS-CoV-2 testing.



Primary Outcome Measures :
  1. Symptoms of COVID-19 in household members of participating children in the subsequent 14 days following enrollment [ Time Frame: 14 days ]
    The clinical secondary attack rate (SAR) for households of participating children, which will be compared to generate the relative SAR for households of children with varying case and symptom statuses.


Secondary Outcome Measures :
  1. Viral Load of SARS-CoV-2 in positive children [ Time Frame: 14 days ]
    The difference in typical viral loads between children of different symptom and case statuses, as well as those with and without clinical secondary cases.


Other Outcome Measures:
  1. Presence of epidemiological risk factors for SARS-CoV-2 infection [ Time Frame: 14 days ]
    Risk factors such as exposures, travel, following public health policy. The frequency of such risk factors among participating children will allow for calculation of the relative risk of such factors.


Biospecimen Retention:   Samples With DNA
SARS-CoV-2 Testing will be performed according to local public health and institutional guidelines. For any participants who tested positive for the presence of SARS-CoV-2, an aliquot of the corresponding positive test will be obtained. Viral load quantification will be performed on any specimens obtained.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All children younger than 18 years of age presenting to a participating ED who meet institutional surveillance screening guidelines (i.e. present with a non-infectious, non-viral concern) and undergo SARS-CoV-2 testing. The number of children eligible may vary based on evolving SARS-CoV-2 testing procedures, public health policy, and patient volumes.
Criteria

Inclusion Criteria:

  • Younger than 18 years of age
  • Had SARS-CoV-2 NAT testing performed during the ED visit as part of an ongoing active asymptomatic surveillance program:

    1. Exposed (SARS-CoV-2 positive) specific: Was found positive by SARS-CoV-2 NAT testing in the ongoing active surveillance program
    2. Unexposed (SARS-CoV-2 negative/control) specific: Was found negative by SARS-CoV-2 NAT testing in the ongoing active surveillance program

Exclusion Criteria:

  • Presence of any of the following viral symptoms commonly associated with SARS-CoV- 2 infection: fever, cough, dyspnea/difficulty breathing, generalized fatigue/weakness, myalgia (muscle or body aches), chills, feeling very unwell, sore throat, runny nose, gastrointestinal symptoms (vomiting, diarrhea), conjunctivitis, headache, anosmia (loss of smell), ageusia (loss of taste) or rash in the 24 hours preceding the index visit (when the child was tested for the presence of SARS-CoV-2).
  • Previously diagnosed with SARS-CoV-2 infection based on a positive swab or serology (blood) test.
  • Decline to provide informed consent and/or assent, as required

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04853316


Locations
Layout table for location information
United States, Alabama
Children's of Alabama
Birmingham, Alabama, United States, 35233
United States, California
University of California, San Diego - Rady Children's Hospital
San Diego, California, United States, 92123
United States, Massachusetts
Boston Children's Hospital
Boston, Massachusetts, United States, 02115
United States, Texas
Children's Medical Center of Dallas - UT Southwestern
Dallas, Texas, United States, 75235
Canada, Alberta
Alberta Children's Hospital
Calgary, Alberta, Canada, T3B 6A8
Sponsors and Collaborators
University of Calgary
Canadian Institutes of Health Research (CIHR)
Investigators
Layout table for investigator information
Principal Investigator: Stephen Freedman, MD University of Calgary
Layout table for additonal information
Responsible Party: University of Calgary
ClinicalTrials.gov Identifier: NCT04853316    
Other Study ID Numbers: REB20-0609
First Posted: April 21, 2021    Key Record Dates
Last Update Posted: May 18, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Calgary:
COVID19
Household transmission
Pediatrics
Asymptomatic
Public health
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases